Antidepressants and survival in glioma-A registry-based retrospective cohort study

Area of Science:

• Neuro-oncology
• Clinical pharmacology
• Epidemiology

Background:

• Malignant glioma patients frequently experience depression and are treated with antidepressants.
• The impact of antidepressant medication on glioma progression and patient survival remains unclear.
• Understanding this relationship is crucial for optimizing patient care and treatment strategies.

Purpose of the Study:

• To investigate the association between antidepressant medication use and survival outcomes in patients diagnosed with malignant glioma.
• To determine if different classes of antidepressants (SSRIs vs. non-SSRIs) have varying effects on glioma patient survival.

Main Methods:

• A registry-based cohort study was conducted using data from the RISK North database in Sweden.
• Included were 1231 patients with malignant glioma (WHO grades 2, 3, and 4) who had undergone surgery.
• 6400 matched controls without glioma were used for comparison.

Main Results:

• Antidepressant use was significantly more common in glioma patients (27%) than in controls (16%).
• Treatment with antidepressants post-surgery was associated with significantly poorer survival in glioma patients.
• Both SSRIs and non-SSRIs showed a negative association with survival, with Hazard Ratios ranging from 3.26 to 7.71 depending on glioma grade and antidepressant type.

Conclusions:

• The study demonstrates a negative association between antidepressant medication and survival in patients with malignant glioma.
• These findings suggest antidepressants may negatively impact glioma survival, but further research is required to establish causality.
• Clarifying the causal relationship is essential for informing clinical decisions regarding antidepressant use in glioma patients.